Agenda

November 13, 2017
  • 7:30 AM
    Registration and Breakfast
  • 8:15 AM
    Opening Comments from the Chair
    Kaitlyn Proulx
    Managing Director, PDCI
  • 8:30 AM
    Keynote Address: PMPRB
    Assess Regulatory Changes to Determine Their Impact on Your Market Access Strategy
    Tanya Potashnik
    Director, Policy & Economic Analysis Branch, Patented Medicine Prices Review Board

    PMPRB Framework modernization is underway with significant changes pending to both the Patented Medicine’s Regulations and PMPRB Pricing Guidelines. Gather insights on:

    • The latest developments on Health Canada’s proposal to add new factors to the PMPRB’s price ceiling setting process.
    • How the PMPRB might operationalize these factors as part of its new risk-based approach to price regulation.

    Discover what regulatory changes can mean to your market access strategy.

  • 9:00 AM
    Panel Discussion: RWE
    Adopt Innovative Solutions in the Use of Real-world Evidence to Enhance your Decision-making
    Neil Corner
    General Manager - Real World Insight, QuintilesIMS
    Alison Paprica
    Director, Strategic Partnerships, Institute for Clinical Evaluative Sciences
    Brad Millson
    Principal, Health Access & Outcomes, QuintilesIMS

    Governments, payers and healthcare’s other stakeholders increasingly look to incorporate data to support decision-making. Explore innovation in Real-World Evidence to improve the value, efficacy and impact of medicines. Take away strategies to:

    • Enhance efficacy of your medicines on individual patient outcomes
    • Evaluate the impact on the health of the overall populations
    • Partner with your stakeholders to access data

    Prove and improve the value, efficacy and impact of your medicines with RWE.

  • 9:45 AM
    Health Canada
    Improving Access to Necessary Therapeutic Products
    Michèle Chadwick
    Lead, Regulatory Review of Drugs and Devices, Health Canada

    The Regulatory Review of Drugs and Devices (R2D2) initiative is underway. Review the objectives of this initiative to improve access to therapeutic products  Stay up-to-date on:

    • Expanded collaboration with health partners
    • More timely access to drugs and devices
    • Enhanced use of real word data

    Analyze the R2D2 initiative to bolster access to treatment

  • 10:15 AM
    Morning Break
  • 10:45 AM
    Panel Discussion: Oncology drug HTA
    Assess Stakeholders’ Perspectives on HTA Process to Improve Your Submissions
    Deborah Maskens
    Founder, Kidney Cancer Canada
    Laurene Redding
    Independent

    With pCODR review and possible re-review, patients can wait 2 to 4 years for access to innovative cancer treatments. Advance your submission strategy to include broader stakeholder insights. Source Intelligence to:

    • Review current HTA processes, timelines, potential delays
    • Understand the new patient and clinician input processes to pCODR
    • Assess the impact of provincial re-review and pCODR Request for Advice (RFA) on access

    Review the effect of all stakeholder submissions to better strategize your market access strategy

  • 11:30 AM
    Patient Advocacy
    Establish How you Can Help your Users to Optimize Access and Adherence
    Lorna Warwick
    Director, Education & Services, Lymphoma Canada

    Reconciling the urgency of patient need with a thorough HTA process is a growing a challenge. Explore what patients expect from you to improve patient outcomes. Gain insights to:

    • Assess patient inputs in the evaluation of formularies
    • Refine your stakeholder mapping
    • Advance your stakeholder engagement process

    Ensure the patients are at the centre of your strategic planning.

  • 12:00 PM
    Panel Discussion: Private Payers
    Analyze Emerging Trends Among Private Payers and Adapt to Change
    Chris Goguen
    Strategic Pharmaceutical Partnerships Lead, Medavie Blue Cross
    Barbara A. Martinez
    National Practice Leader, Drug Benefits Solutions, Great West Life
    Karen Voin
    Assistant Vice President - Group Benefits and Anti-Fraud, Canadian Life and Health Insurance Association

    The private payer landscape is undergoing significant changes that will impact patient access and how medications are reimbursed. Strengthen your market access strategy with insights into emerging trends in the private payer landscape. Source critical information to:

    • Assess trends among large employers
    • Revise changes in industry leadership and emerging partnerships
    • Review the solutions plan sponsors are considering

    Integrate the employer’s outlook into your market access strategies.

  • 12:30 PM
    Networking Lunch
  • 1:00 PM
    Lunch & Learn

    Driving Value Out of Upstream Data

  • Common Drugs
    • 1:30 PM
      Case Study: New Product Pricing
      Increase Patient Access with Differential Pricing Considerations
      Rosemarie Childerhose
      Lead, Patient Relations and Government Relations, Valeant Pharmaceuticals

      In a highly regulated pricing market pharmaceutical companies look to incorporate differential pricing domestically to increase patient access. Review how to approach Canadian “differential pricing” to increase patient access. Gain insights to:

      • Analyze how price impact patient’s ability to choose a product that best meets her/his needs
      • Price your products while addressing changing market expectations
      • Increase access to priority products with portfolio pricing in different markets

      Join us for a timely and stimulating discussion that will inform your pricing strategy development for future launch products.

    • 2:00 PM
      Case Study: Managing Data
      Structure your Data from Real-world Setting to Enhance your Value Proposition
      Karine Alloul
      Senior Manager, Health Economics & Health Outcomes, Sanofi

      Real-world evidence can be a challenge due to the complexity of the data. Learn from Sanofi’s experience to strategize your data management. Gain practical tips to:

      • Address specific patient outcomes within your researches
      • Analyze the impact of RWE on your submission/li>
      • Review your value proposition

      Gain practical insights on the challenges of RWE from Sanofi’s experience.

    • 2:30 PM
      Setting the Tone – A Renewed Approach
      Collaborate with Key partners to Improve Access and Affordability of Medicines
      Pamela Fralick
      President, Innovative Medicines Canada

      Collaboration is key to stimulate the life sciences sector in our country. Meet shared objectives with public partners to advance access and affordability.

    Speciality Drugs – Oncology
    • 1:30 PM
      Case Study: ODANO
      Analyze ODANO’s Work with Patients to Anticipate the Demand Side of the Market
      Alan Birch
      Drug Access Navigator, ODANO

      ODANO is a new Ontarian drug access navigator to facilitate cancer drug coverage. Analyze the impact of drug access navigators on patients to increase speed of reimbursement. Gain insights on:

      • Educating patients
      • Establishing and enhancing partnerships
      • Best practice sharing among patients

      Explore what drug access navigators can do to increase the speed of reimbursement.

    • 2:00 PM
      Oncology Biosimilars
      Market Access considerations for Biosimilars
      Heather Francis
      Director of Healthcare and Innovation, Roche Canada

      The next wave of biosimilars is about to enter the Canadian market and present unique issues not part of the current landscape. Learn about the considerations associated with institutionally-based products such as oncology monoclonal antibodies, including:

      • Pharmaceutical policy related to reimbursement
      • Regulatory review, naming convention, health technology assessment, and public funding
      • Key differences related to levels of evidence, switching and funding mechanisms

      Assess the considerations for Oncology biosimilars.

    • 2:30 PM
      Industry Expert
      Turning Policy into Action to Achieve your Patient Access Goals

      Demands on more value for healthcare dollars are driving policy and
      systems-wide changes. Ensure you play a role in enabling patient
      access and quality of care. Sources strategies to:

      • Build an integrated patient access strategy
      • Motivate decision-makers to keep the cost to the patients in mind
      • Integrate digital advocacy into your plans

      Strategize and plan accordingly to get the attention of market access
      decision-makers.

  • 3:00 PM
    Afternoon Break
  • 3:30 PM
    Regional Health Authority
    Assess the National Formulary Collaborative (NFC) from the Perspective of Alberta’s Regional Health Authority
    Jeremy Slobodan
    Director, Drug Utilization, Information & Stewardship, Alberta Health Services

    Regional health authorities are working to improve alignment with public drug plans and utilize the best available evidence when reviewing hospital only drugs. Analyze the NFC and the hospital formulary review process in Alberta to improve your market access strategy. Gain insights to:

    • Review NFC, its purpose and its impact on manufacturers and payers
    • Comprehend policy alignment with CADTH and Alberta Drug Benefit List
    • Provide an overview of the formulary review process in Alberta and the challenges for coverage

    Evaluate the evolution of decision-making at the regional level and its effects on your organization. 

  • 4:00 PM
    Panel Discussion: Companion Diagnostic Tests
    Anticipate a Need to Include Relevant Companion Diagnostics Tests with Your New Drug Submissions
    Greg Rutherford
    Director - Pharmaceutical Solutions, McKesson Canada
    Christopher Trevors
    National Director - Genetic Health Solutions, Dynacare
    John Anacleto
    Director of Payer Relations, McKesson Canada

    CDR guideline are likely to change and major lab diagnostic testing companies and patient support programs are pro-acting for this eventuality. Adapt to changing CDR guidelines and Improve your submissions with companion diagnostic tests. Source intelligence to:

    • Highlight changes to CDR
    • Discuss commercialization of companion diagnostics
    • Review how payers intend to integrate these requirements into their coverage plans

    Strengthen your new submission with relevant companion diagnostic tests.

  • 4:45 PM
    Afternoon Keynote: British Columbia Update
    Align your Strategy with the Payer Policies to Increase the Speed of Reimbursement
    Eric Lun
    Executive Director - Drug intelligence optimization, BC Government
    Mitch Moneo
    Acting Assistant Deputy Minister, BC Ministry of Health

    With long negotiations and shrinking budgets, patients are likely to wait longer to get reimbursed. Stay in tune with payer priorities to ensure that your patients are quickly reimbursed. Develop your action plan to:

    • Clarify coverage criteria
    • Define and demonstrate value to the payers
    • Advance your listing agreements

    Adapt your value proposition to ensure the coverage of your treatments.

  • 5:25 PM
    Conference Adjourns to Day Two
  • 5:30 PM
    Executive Evening Reception
November 13, 2017
November 14, 2017
  • 7:00 AM
    Registration and Breakfast
  • 8:15 AM
    Opening Comments from the Chair
    John-Paul Dowson
    Managing Director, Roubaix Strategies Inc
  • 8:30 AM
    Keynote: pCPA Update
    Review pCPA Approach to Negotiation and Pricing to Prepare your Submissions Better
    Imran Ali
    Senior Manager, pan-Canadian Pharmaceutical Alliance
    Brad Alyward
    Manager, Business Solutions, Nova Scotia Department of Health and Wellness

    The pCPA changed notably in the past few years and its approach to negotiation has evolved. Reassess your expectation and improve your submissions. Source Intelligence to:

    • Enhance the use of your company’s research and marketing resources
    • Improve consistency of decisions and achieve lower drug costs
    • Facilitate communication between your company, the federal government and the provinces

    Revise changes at pCPA to enhance your submission process.

  • 9:30 AM
    Panel: Data Insights
    Advance Evidence Generation to Improve your Organization’s Access to Market
    Alison Drinkwater
    Senior Director, Strategic Consulting, Innomar Strategies

    The trends occurring in the public and private plan designs are essential to developing your market access strategy. Leverage data insights within the patient support program environment to move from a reimbursement focus to an evidence generation focus. Discover insights to:

    • Link plan design with patient access
    • How patient support programs can generate Real World Evidence in decision making
    • Identify the trends that affect different products

    Analyze how the changing reimbursement landscape is impacting market access to optimize your company’s access strategies.

  • 10:00 AM
    Panel: Quebec’s Market
    Everything You Always Wanted to Know about Quebec’s Market Access but Afraid to Ask!
    Alain Madgin
    Senior Vice President, Citoyen Optimum

    Since the 2014 general election, the Quebec Government has shown the desire to proceed with major cut backs in the healthcare system. Wide-ranging reforms, aimed at conclusively fixing Quebec’s health system, are impacting service providers, manufacturers, healthcare professionals, and patients. Explore how your organization can position itself in this turbulent time. Master the success factors to:

    • Understand the regulatory framework in place and the policy environment;
    • Explore future issues and challenges;
    • List your projects in the government's vision.

    List your projects in the government's vision.

  • 10:45 AM
    Morning Break
  • 11:15 AM
    CDR Update
    Evaluate CDR’s Priority to Minimize Delays in your Submissions

    CADTH CDR made changes to improve transparency and HTA timelines. Explore what these changes can do to streamline your submissions. Source intelligence on:

    • New advanced notifications for expedited Health Canada Review
    • Closer partnerships between CDR and pCPA
    • Changes in the 4th HTA guidelines

    Align with new CDR guidelines to advance your approval processes.

  • Common Drugs
    • 11:45 AM
      Case Study: R&D Alliance
      Support Growth in Your Early Stage Pipeline to Improve Access to Treatments
      Amyn Sayani
      Interim Director – Health Economics and Outcomes Research & Specialty Pharmaceuticals, Medical Affairs, GSK

      Collaboration is a crucial aspect of R&D and early stage of new product launches. Ensure a successful launch for your new products and advance access to treatments. Gain insights to:

      • Advance your transfer of technology
      • Strengthen your R&D collaborations
      • Demonstrate the value of your new products

      Bolster your product development and make innovative health treatment available on the market.

    • 12:15 PM
      Industry Expert: National Pharmacare
      Prospects for National Pharmacare
      Neil Palmer
      Founder & Principal Consultant, PDCI

      National Pharmacare continues to be the focus of research studies and political initiatives. Analyze the issues and offer a critical assessment of the latest research and the prospects for universal coverage of prescription medicines in Canada. Gain insights on:

      • Defining national pharmacare
      • Critical assessment of research studies
      • Influence of OHIP+ on the national discussion
      • Federal PBO analysis
      • Getting to the core issues of coverage & cost savings

      Review the latest research and the prospects for universal coverage of prescription medicines in Canada.

    Speciality Drugs – Rare Diseases
    • 11:45 AM
      Case Study: Orphan Drugs
      Collaborate with Stakeholders to Develop your Products and Improve Patient Outcomes
      Eric Tse
      General Manager, Canada, Shire Pharmaceutical

      Small markets can impede the development of orphan drugs, but collaboration can alleviate some restraints. Build partnerships to develop your new products and secure revenue opportunities. Build a roadmap to:

      • Explore funding and joint research opportunities
      • Gather inputs from patients
      • Optimize your company’s ROI in a small market

      Work with your stakeholders to increase patient access to treatments.

    • 12:15 PM
      Industry Expert: Pricing
      Anticipate Pressure on Price to Reduce Delays in the Listing of your High Price Drugs

      Although speciality drugs represent 5% of prescriptions, they represent 20–25% of the benefits paid. Review your pricing strategy to reduce delays in listing.

      • Improve your HEOR
      • Develop your pricing strategy for three-tiered drug plans
      • Anticipate demand side for your new patients

      Plan your negotiation strategy to streamline listing of your high priced drugs.

  • 12:45 PM
    Networking Lunch
  • Generic Drugs
    • 1:45 PM
      Employer Perspective
      Encourage Sponsors to Cover Your Drug and Ascertain How They Can Be Incorporated into Your Access Strategy

      Private sponsors need a clear value-proposition to enhance their benefit plans. Clarify your value proposition to ensure employees access to the best treatments. Gain practical insights to:

      • Align your treatments with wellness programs
      • Promote cost-reduction strategies that go beyond generic substitution
      • Address short-comings of stepped drug plans

      Include sponsor insights in your value proposition to increase patient access to treatments.

    • 2:15 AM
      Case Study: Competitive Value Price Initiative
      Reduce your Drug Costs to Secure Access the Generic Drugs Market

      The Pan-Canadian Competitive Value Price Initiative for Generic Drugs reduces the price by 15–18% of the brand price. Protect your market access by adapting to lower drug prices. Build a roadmap to:

      • Identify product impacted by the initiative
      • Review updates on the initiative
      • Adjust your public payer strategy

      Overcome the challenges of shrinking drug prices to enhance market access.

    Brand Drugs
    • 1:45 PM
      Payer Partnerships
      Optimize your Access When Negotiating With Group Purchasing Organizations
      Doug Nanton
      Market Access & Government Affairs -Western Canada & Ottawa, Valeant Canada

      The growing transparency at CADTH and shrinking hospital budgets are changing the perspective of GPOs. Adapt to GPO’s approach to ensure your access to hospital and community care. Create a roadmap to:

      • Analyze the work of hospital review boards within GPOs
      • Clarify purchase criteria
      • Address cost concerns

      Overcome the challenges of shrinking government budgets when dealing with GPOs.

    • 2:15 PM
      Case Study: Global Price and Market Access
      Refine your Global Negotiation Strategy to Optimize your Access

      Adapting a global pricing strategy to Canadian markets continues to be a challenge. Work efficiently with global affiliates and Canadian payers to improve your negotiations. Source insights to:

      • Involve your global pricing team
      • Tailor your value proposition
      • Advance your marketing strategy

      Enhance your commercialization planning in a global context.

  • 2:45 PM
    Biosimilar
    Review Pricing Trends in Biosimilars and its Impact on the Access to Treatments
    Nadia Turchetta
    Executive Director of Biosimilars, Sandoz Canada

    Biosimilar technology has greatly evolved in the past decade and it offers more affordable option to patients. Review pricing trends to optimize your access to market and improve access to treatment. Take away new ideas to:

    • Assess new opportunities for healthcare systems
    • Comply to regulatory frameworks
    • Anticipate price changes on your biologic drugs

    Review biosimilars trends to provide a greater access to treatments.

  • 3:30 PM
    Conference Adjourns
November 14, 2017
November 15, 2017
  • 9:00 AM - 12:00 PM
    Workshop A: Price Listing Agreement
    Drive Successful pCPA Strategies and PLAs to Solidify your Market Access Strategies
    Colin Vicente
    Managing Director, Pivina

    The pan-Canadian Pharmaceutical Alliance (pCPA) has established their officce and become a formal process for getting new drugs to the market. Source insights to manage and optimize your submission. Tap into both public and private perspectives in this interactive workshop and walk away with knowledge to:

    • Understand the pCPA process and submissions
    • Prepare for pCPA in the planning stages of your products
    • Use pricing models to assist your product’s positioning during negotiations
    • Gain an understanding of different types of Canadian PLAs
    • Take advantage of potential opportunities in private sector PLAs

    Develop your successful pCPA strategy through this hands-on interactive workshop.

  • 1:00 PM - 4:00 PM
    Workshop B: Pharmaceutical Negotiations 2.0
    Take Your Negotiating to the Next Level
    John-Paul Dowson
    Managing Director, Roubaix Strategies Inc

    So, you know what pCPA wants and how payers operate. Now what? How can you possibly negotiate value in the face of hard positions?

    • This half-day hands-on workshop will engage you in important negotiating concepts that can help you achieve better mutual value when negotiating with payers.
    • Participants will work through case examples to plan, practice and launch live moderated value-based negotiations
    • Building upon your payer knowledge, you will learn how to dig behind known positions to uncover and address the underlying interests of Canadian payers.

    This is a unique opportunity for participants. The program brings you more than 40 years of combined pharmaceutical experience, blending this with strategies from the world-renowned “Harvard Negotiation Project”, to deliver a truly unique and customized negotiation program for today’s pharmaceutical professionals.

November 15, 2017

Download Brochure - Gain new ideas and practical strategies for implementation

  • This field is for validation purposes and should be left unchanged.